KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.95

Health-related Quality of Life in Intermediate- or High-risk Patients Treated With Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study.

Miikka Lehtonen, Jorma Sormunen, Marie Hjälm-Eriksson, Camilla Thellenberg-Karlsson, Teppo Huttunen, Claes Ginman, Pirkko-Liisa Kellokumpu-Lehtinen, Investigators of the Scandinavian Prostate Cancer Group Study No 13

Anticancer Res 42(1) 87-92

PMID34969712
PMCID-
DOI10.21873/anticanres.15460
发表日期2021-12-31
入排依据:The record is a Phase III randomized controlled trial in oncology, but it reports only health-related quality of life outcomes, not the required survival, progression, recurrence, death, hazard, or time-to-event efficacy outcomes.
摘要

摘要

BACKGROUND/AIM: The goal of this study was to investigate whether health-related quality of life (HRQoL) was affected in patients with high- or intermediate-risk localized prostate cancer treated with docetaxel following radiation therapy (RT). PATIENTS AND METHODS: A total of 376 patients treated with RT and androgen deprivation were randomized to receive 6 cycles of docetaxel 75 mg/m2 (N=188, Arm A) or surveillance (N=188, Arm B). FACT-P HRQoL questionnaires were gathered at baseline, six months and 1, 2 and 4 years after randomization. The data were analysed using analysis of covariance. RESULTS: FACT-P scores decreased in Arm A at the end of treatment and remained unchanged in Arm B (p<0.0001). The HRQoL scores in Arm A matched Arm B in the 1-year follow-up (p=0.0528) and remained similar in further follow-up. CONCLUSION: Docetaxel transiently decreased HRQoL during chemotherapy but not after treatment for up to four years of follow-up.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。